{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:35:45Z","timestamp":1791088545192,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"am","delay-in-days":323,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA013148"],"award-info":[{"award-number":["P30CA013148"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI R00CA215604"],"award-info":[{"award-number":["NCI R00CA215604"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["DP2CA261453"],"award-info":[{"award-number":["DP2CA261453"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 R01CA276540 R01CA279143"],"award-info":[{"award-number":["R01 R01CA276540 R01CA279143"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA240589"],"award-info":[{"award-number":["R01CA240589"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-18-006-01-CCE"],"award-info":[{"award-number":["RSG-18-006-01-CCE"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.nucmedbio.2024.108918","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T15:37:33Z","timestamp":1715182653000},"page":"108918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["[18F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response"],"prefix":"10.1016","volume":"134-135","author":[{"given":"Kaytlyn C.","family":"McNeal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick N.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Lapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna G.","family":"Sorace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Larimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2024.108918_bb0005","series-title":"Annual Review of Pathology: Mechanisms of Disease","first-page":"223","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0010","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0015","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/cancers15030793","article-title":"Complete response in metastatic clear cell renal cell carcinoma patients treated with immune-checkpoint inhibitors: remission or healing? How to improve patients\u2019 outcomes?","volume":"15","author":"Thouvenin","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0025","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","article-title":"Hypoxia and cancer","volume":"85","author":"Brahimi-Horn","year":"2007","journal-title":"J Mol Med"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0030","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical challenges of immune checkpoint inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2020.12.020","article-title":"Metabolic adaptation in hypoxia and cancer","volume":"502","author":"Paredes","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0045","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/med.21771","article-title":"The role of hypoxia-inducible factor 1 in tumor immune evasion","volume":"41","author":"You","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0050","series-title":"Seminars in nuclear medicine","first-page":"451","article-title":"Hypoxia positron emission tomography imaging with 18F-fluoromisonidazole","author":"Lee","year":"2007"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0055","series-title":"Seminars in nuclear medicine","first-page":"400","article-title":"18F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization","author":"Vallabhajosula","year":"2007"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1078-0432.CCR-21-2394","article-title":"18F-FMISO PET imaging identifies hypoxia and immunosuppressive tumor microenvironments and guides targeted evofosfamide therapy in tumors refractory to PD-1 and CTLA-4 inhibition","volume":"28","author":"Reeves","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0065","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2016.79","article-title":"Hypoxia-activated prodrugs: paths forward in the era of personalised medicine","volume":"114","author":"Hunter","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/ars.2021.0176","article-title":"Hypoxia imaging as a guide for hypoxia-modulated and hypoxia-activated therapy","volume":"36","author":"Brender","year":"2022","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0075","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejca.2017.07.043","article-title":"The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma","volume":"84","author":"Constantinidou","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0080","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-20-4118","article-title":"A phase I dose-escalation study to evaluate the safety and tolerability of Evofosfamide in combination with Ipilimumab in advanced solid MalignanciesPhase I study of Evofosfamide and Ipilimumab in solid tumors","volume":"27","author":"Hegde","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0085","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1088\/0031-9155\/50\/10\/002","article-title":"A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia","volume":"50","author":"Thorwarth","year":"2005","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0090","first-page":"11","article-title":"Exploring tumor heterogeneity using PET imaging: the big picture","author":"Bailly","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11307-016-0994-1","article-title":"Quantitative [18 F] FMISO PET imaging shows reduction of hypoxia following trastuzumab in a murine model of HER2+ breast cancer","volume":"19","author":"Sorace","year":"2017","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0100","first-page":"17625","article-title":"Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer","volume":"20","author":"Lima","year":"2023","journal-title":"Math Biosci Eng"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0105","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0969-8043(93)90110-V","article-title":"An efficient radiosynthesis of [18F] fluoromisonidazole","volume":"44","author":"Lim","year":"1993","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0110","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/BF02349874","article-title":"Preparation of [18 F] fluoromisonidazole by nucleophilic substitution on THP-protected precursor: yield dependence on reaction parameters","volume":"240","author":"Patt","year":"1999","journal-title":"J Radioanal Nucl Chem"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0115","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.nucmedbio.2005.03.010","article-title":"Fully automated one-pot synthesis of [18F] fluoromisonidazole","volume":"32","author":"Tang","year":"2005","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213111","article-title":"Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer","volume":"14","author":"Kroenke","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.112.109330","article-title":"High reproducibility of tumor hypoxia evaluated by <sup>18<\/sup>F-Fluoromisonidazole PET for head and neck cancer","volume":"54","author":"Shozo","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0130","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"100787","author":"Kopecka","year":"2021","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0135","unstructured":"Chouaib S, Noman MZ, Kosmatopoulos K, and Curran MA. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer."},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0140","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tips.2019.07.001","article-title":"Tumor vasculatures: a new target for cancer immunotherapy","volume":"40","author":"Liu","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.15252\/emmm.201606674","article-title":"PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy","volume":"9","author":"Azad","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.nucmedbio.2024.108918_bb0150","first-page":"11","article-title":"Molecular imaging of oxygenation changes during immunotherapy in combination with paclitaxel in triple negative breast cancer","author":"Napier","year":"2023","journal-title":"Biomedicines"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T14:37:48Z","timestamp":1718462268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805124000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":30,"alternative-id":["S0969805124000441"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108918","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[18F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108918"}}